The rise of artificial intelligence (AI) has thrown pharmaceutical companies and medical device into a race to develop new products and services to open the age of AI healthcare.Korea also has been approving, slowly but steadily, new AI medical devices for use in the clinical field while setting up new regulations and application methods to speed up the new sector’s development. Not all AI
Since IBM introduced Watson, an artificial intelligence-based medical device has become one of the hottest keywords in the biomedical sphere. Lunit, abbreviated from “learning unit,” is a venture company devoted to developing such advanced medical image analytics and novel imaging biomarkers using AI and deep learning technology.The company is focusing on radiology and plans to make do
The global genomics market is expected to reach $23.8 billion by 2022, growing 10 percent annually from $14.7 billion in 2017. Genomics is a rapidly growing field, with the market creating an enormous amount of data annually.Estimates show 2.4 exabytes are created each year. To put things into perspective, social media platforms Twitter generates 1.17 petabytes annually while Youtube creates 1
Artificial intelligence (AI)-based drug discovery is now the hottest keyword in the biomedical sphere with more than 70 firms entering the field this year alone.Standigm, an AI-based drug discovery startup founded in 2015, has aimed to use its self-developed technology and long-standing expertise to produce real-life results and stand out from the crowd.The firm is now preparing to break t
MedySapiens is actively using bioinformatics and big data in providing premium healthcare. Unlike most other big data companies, however, the company applies its AI and BT to develop a clinical decision support system (CDSS) not just for humans but also for pets. With more than 1 out of 4 households in Korea living with pets, their lifestyles are becoming more and more similar to that of human
The human DNA consists of about 3 billion bases – one mutation could cause a rare disease that takes an average of five to 20 years to diagnose. Rare disease affects fewer than 1 in 2,000 people. About 7,000 kinds exist. Korean bioinformatics firm 3billion offers a solution that scans for DNA mutations and help physicians diagnose rare diseases faster and more accurately not just for wealthy c
Korea Biomedical Review is running a series on innovative healthcare startups that feature next-generation technology to shake up the industry. -Ed. “If DaVinci stands for surgical robots, Surgical Mind will represent virtual reality-based microsurgery training solutions.”So said Kim Il, founder and CEO of Surgical Mind, a virtual reality (VR)-based medical training device and sof
“Korea drugmakers can make giant leaps with big data.”Yi Hong-gi, CEO of Corezetta, a pioneer in the field of healthcare big data, jumped to that conclusion while outlining big data’s unlimited potential and stressing the need for the companies to understand how to use it properly.Yi is a leading expert in using the big data at Health Insurance Review and Assessment Service (HIRA) to help